ClinicalTrials.gg
RecruitingNCT07656753Updated Jun 18, 2026

Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy

An Early Phase 1 interventional study of PUMCH-E111 Injection(Low dose) and PUMCH-E111 Injection(High dose) in Inherited Retinal Dystrophy and Inherited Retinal Disease, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by Peking Union Medical College Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Feb 2026, registered Jun 2026).
  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Retinal Dystrophies with a site in China — 6 open to participants now, 9 under way, 1 of them phase 3. Retinal Dystrophies · China.

Started
2026
the only one that year
Phase 1
4 of 10
3 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Peking Union Medical College Hospital

Among the 10 studies in Retinal Dystrophies with a site in China, this one is the only one that started in 2026, is one of 4 in phase 1, and was the 10th registered.

Retinal Dystrophies

60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.

Browse Retinal Dystrophies studies →

Open to participants now

6 of the 10 studies in Retinal Dystrophies with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Retinal Dystrophies with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and efficacy of PUMCH-E111 injection in subjects with RLBP1 related Inherited Retinal Dystrophy.

Read the detailed description

This is an open-label, single-center, dose-escalation study. One eye of each participant will receive a single intravitreal injection of PUMCH-E111. Participants will be followed for 52 weeks after which they will continue to be followed for up to 5 years after enrollment.

03

Conditions studied

  • Inherited Retinal Dystrophy
  • Inherited Retinal Disease

Browse trials for

Keywords

  • inherited retinal dystrophy
  • RLBP1 mutation
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participate and sign the form;
  2. Age between 18-55 years old, gender is not limited;
  3. Clinical diagnosis of IRD caused by RLBP1 mutations;
  4. For the study eye, residual visual field within the 30° central field is tested using Program G or Program LVC on the Octopus perimeter;
  5. At screening, the blood pregnancy test result of females of (e.g., females who have not undergone surgical sterilization or less than 1 year after menopause) is negative. Male and female subjects of childbearing potential agree to use effective throughout the study and for at least 12 months after dosing.

Exclusion criteria

Exclusion Criteria:

  1. Opacity of refractive media or inability to dilate pupils in the study eye that significantly interferes with visual acuity detection, anterior segment or fundus assessment;
  2. Presence of diabetic retinopathy, retinal vein occlusion, pathological myopia, retinal detachment, or other conditions in the study eye that are assessed by the investigator as affecting the safety of the subject or the validity of the study;
  3. Active intraocular or periocular infection (such as blepharitis, conjunctivitis, keratitis, scleritis, etc.) in the study eye;
  4. History of vitreous hemorrhage in the study eye within 6 months prior to screening;
  5. Any intraocular surgery in the study eye within 3 months prior to screening;
  6. History of glaucoma in either eye;
  7. History of uveitis in either eye;
  8. Those with diffuse intravascular coagulation and obvious bleeding tendency (such as hemoptysis, hematemesis, severe purpura, etc.) within 3 months before screening;
  9. History of myocardial infarction, unstable angina, coronary revascularization, cerebrovascular accident (including ), history of other thromboembolic diseases (such as thromboembolic angiitis, pulmonary embolism, deep vein thrombosis, portal vein thrombosis, etc.), (NYHA) grade ≥ II cardiac insufficiency, severe unstable ventricular arrhythmia, within 6 months prior to screening;
  10. Subjects with systemic immune diseases (including systemic lupus erythematosus, ankylosing spondylitis, rheumatoid arthritis, etc.);
  11. Diabetic patients with any of the following conditions: Known macrovascular complications or Glycosylated at screening()>7.5% or Those who have received more than two oral hypoglycemic drugs or received insulin or GLP-1 receptor agonists therapies;
  12. Hypertensive patients with poor blood pressure control (defined as: systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg when the subject is seated after receiving antihypertensive medication);
  13. Any uncontrollable clinical illness (such as severe psychiatric, respiratory and other systemic diseases and history of malignant tumors);
  14. Subjects with abnormal liver and kidney function: (ALT)/aspartate aminotransferase (AST) ≥ 2 times the ; Total ≥ 1.5 times the upper limit of normal, creatinine and urea/urea nitrogen ≥ 1.5 times the upper limit of normal;
  15. Subjects with abnormal coagulation function: (PT) > upper limit of normal value of 3 seconds or activated partial thromboplasting time (APTT) > upper limit of normal value of 10 seconds; Haemoglobin (HGb) \< 10 g/dL;
  16. Those who are positive for surface antigen (HBsAg), virus (HCV) antibody, treponema pallidum antibody and (HIV) antibody;
  17. Those who are known to be allergic to the therapeutic drugs or diagnostic drugs used in the study protocol, including the products, etc.;
  18. Those who have used anticoagulant or antiplatelet drugs within 7 days before dosing;
  19. Currently using or may need to use drugs that can cause crystalline toxicity or retinal toxicity (such as deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, ethambutol, etc.);
  20. Those who have a history of surgical operation within 1 month before screening, and/or currently have unhealed wounds (wound degree> stage III), moderate to severe ulcers, and fractures;
  21. Subjects with systemic infectious diseases requiring systemic treatment (oral, intramuscular or intravenous) at the time of screening;
  22. Those who have received any AAV gene therapy products in the past;
  23. Pregnant or lactating females;
  24. Those who have participated in any clinical trial of drugs (excluding vitamins and minerals) within 3 months before screening;
  25. Other individuals who need to be excluded, as determined by the investigator
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    PUMCH-E111 Treatment Arm(Low dose)

    Intraocular injection of a single low dose of PUMCH-E111

    Genetic: PUMCH-E111 Injection(Low dose)

  • Experimental
    PUMCH-E111 Treatment Arm(High dose)

    Intraocular injection of a single high dose of PUMCH-E111

    Genetic: PUMCH-E111 Injection(High dose)

Interventions

  • GeneticPUMCH-E111 Injection(Low dose)

    Single intravitreal injection

  • GeneticPUMCH-E111 Injection(High dose)

    Single intravitreal injection

06

What researchers measure

Primary outcomes

  1. Incidence of DLTs

    Number and proportion of dose limited toxicity (DLTs)

    Time frame: 4 weeks

  2. Incidence of AEs

    Number and severity of overall and ocular Adverse Events (AEs)

    Time frame: 52 weeks

  3. Incidence of SAEs

    Number and severity of overall and ocular Serious Adverse Events (SAEs)

    Time frame: 52 weeks

Secondary outcomes

  1. Visual function

    Change from baseline in BCVA (Best Corrected Visual Acuity) (ETDRS)

    Time frame: 52 weeks

  2. Visual function

    Change from baseline in LLVA (Low-Luminance Visual Acuity) (ETDRS)

    Time frame: 52 weeks

  3. Visual function

    Change from baseline in the mean value of the photosensitivity threshold (Dark adaption Threshold Curve)

    Time frame: 52 weeks

  4. Visual function

    Change from baseline in mean sensitivity (MS) (Static visual field)

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
    Recruiting
    • Ruifang Sui, MD, PhD · Contacthrfsui@163.com · +8613511017280
    • Ruifang Sui, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 18, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
May 31, 2031
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07656753
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Feb 3, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
May 31, 2031 (estimated)
Last update
Jun 18, 2026

Study contacts

Ruifang Sui, MD, PhD
Contact
hrfsui@163.com
+8613511017280
Ruifang Sui, MD, PhD
principal investigator · Peking Union Medical College Hospital, Department of Ophthalmology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion